Results 31 to 40 of about 10,449 (205)

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources

Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy

Advanced Science, EarlyView.
Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee, Chul‐Gyun Lim, Pothiappan Vairaprakash, Jong‐Min Kim, Jiyoon Kim, Ji‐Young Park, Klaus M. Hahn, Hyunbo Shim, Hae Woong Choi, Tobias S. Ulmer, Soon Jun Hong, Chungho Kim   +11 more
wiley   +1 more source

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant

Journal of Interventional Medicine, 2020
Objective: To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa antagonists (GPI) eptifibatide and tirofiban.
Qiao Deng, Shichao Zhang, Mingzhou Li, Guozhong Zhang, Wenfeng Feng   +4 more
doaj   +1 more source

Standardizing the Clinical Approach to Cancer Therapy‐Related Cardiac Dysfunction: Applying Cardio‐Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Introduction and Methods Cancer therapy–related cardiac dysfunction (CTRCD) is a well established and potentially life‐threatening complication of contemporary oncologic treatment. Although comprehensive cardio‐oncology guidelines have been developed, their integration into routine hematology and oncology practice remains inconsistent.
Abdelrahman Ali, Suparna C. Clasen, Anne Blaes, Stephen Casselli, Anita Deswal, Susan Halli Demeter, Gregory Durm, Anecita Fadol, Alessandra Ferrajoli, Michael G. Fradley, Joerg Herrmann, Borja Ibanez, Sue Koob, Bogda Koczwara, Kasey J. Leger, Jennifer E. Liu, Teresa López‐Fernández, Alexander R. Lyon, N. G. Choon Ta, John Teerlink, Eric H. Yang, Susan Dent, Daniel Lenihan   +22 more
wiley   +1 more source

Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window

Clinics, 2021
OBJECTIVES: To investigate the safety and efficacy of combined tirofiban-ozagrel therapy for treating progressive stroke patients out of thrombolytic therapy time window.
Huiying Zhang, Lei Zheng
doaj   +1 more source

Association of the Triglyceride–Glucose (TyG) Index and TyG‐BMI With 1‐Year Outcomes Following Endovascular Treatment in Acute Basilar Artery Occlusion

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
TyG and TyG‐BMI independently predicted unfavorable functional outcome and 1‐year mortality after endovascular treatment for acute basilar artery occlusion. Higher values were associated with worse prognosis, with TyG‐BMI showing a sex‐specific effect on mortality, confined to men.
Qiuting Wang, Haodong Li, Yuxin Chen, Na Liu, Lu Yang, Chuanjie Wu, Wenbo Zhao, Longfei Wu, Liqun Jiao, Sijie Li, Qingfeng Ma, Xunming Ji, Chuanhui Li   +12 more
wiley   +1 more source

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease [PDF]

, 2001
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials
Salam Amar M, Suwaidi Jassim
core   +2 more sources

Mechanical Solitaire Thrombectomy with Low-Dose Booster Tirofiban Injection [PDF]

Neurointervention, 2016
PurposeMechanical thrombectomy using a Solitaire stent has been associated with a high recanalization rate and favorable clinical outcome in intra-arterial thrombolysis.
Duck-Ho Goh, Sung-Chul Jin, Hae Woong Jeong, Sam Yeol Ha   +3 more
doaj   +1 more source

Case report: reuse of tirofiban leads to very severe thrombocytopenia

Frontiers in Cardiovascular Medicine, 2023
BackgroundTelofiban is a class of small molecule non-peptide tyrosine derivatives containing RGD sequences. It is the only platelet surface glycoprotein (GP) IIb/IIIa receptor antagonist (GPI) currently marketed in China.
Yuqing Li, Jiuchun Qiu, Yi Gao, Guangping Li   +3 more
doaj   +1 more source

Prevention of In‐Stent Restenosis After PCI by Saponin Natural Products: Inhibition of Platelet Activation

Journal of Cellular and Molecular Medicine, Volume 30, Issue 3, February 2026.
ABSTRACT Percutaneous coronary intervention (PCI) enables coronary revascularisation and restores haemodynamic stability but also carries risks of delayed complications including in‐stent restenosis (ISR), a chronic progressive disease with endovascular damage after PCI, which compromises the long‐term efficacy of PCI.
Xueli Lei, Chunlei Lv, Yu Zhang, Zhiyu Li, Hao Shen, Li Zhu   +5 more
wiley   +1 more source